CATAPRES-TTS-3 Drug Patent Profile

When do Catapres-tts-3 patents expire, and what generic alternatives are available?

Catapres-tts-3 is a drug marketed by Lavipharm and is included in one NDA.

The generic ingredient in CATAPRES-TTS-3 is clonidine. There are twenty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Catapres-tts-3

A generic version of CATAPRES-TTS-3 was approved as clonidine by MYLAN TECHNOLOGIES on July 16^th, 2010.

Summary for CATAPRES-TTS-3

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	19
Patent Applications:	3,253
DailyMed Link:	CATAPRES-TTS-3 at DailyMed

Recent Clinical Trials for CATAPRES-TTS-3

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rigshospitalet, Denmark	Phase 2/Phase 3
Deventer Ziekenhuis	Phase 3
Queen's University, Belfast	Phase 3

See all CATAPRES-TTS-3 clinical trials

Pharmacology for CATAPRES-TTS-3

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists

US Patents and Regulatory Information for CATAPRES-TTS-3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lavipharm	CATAPRES-TTS-3	clonidine	SYSTEM;TRANSDERMAL	018891-003	Oct 10, 1984	AB	RX	Yes	Yes

Expired US Patents for CATAPRES-TTS-3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lavipharm	CATAPRES-TTS-3	clonidine	SYSTEM;TRANSDERMAL	018891-003	Oct 10, 1984
Lavipharm	CATAPRES-TTS-3	clonidine	SYSTEM;TRANSDERMAL	018891-003	Oct 10, 1984
Lavipharm	CATAPRES-TTS-3	clonidine	SYSTEM;TRANSDERMAL	018891-003	Oct 10, 1984
Lavipharm	CATAPRES-TTS-3	clonidine	SYSTEM;TRANSDERMAL	018891-003	Oct 10, 1984
Lavipharm	CATAPRES-TTS-3	clonidine	SYSTEM;TRANSDERMAL	018891-003	Oct 10, 1984

International Patents for CATAPRES-TTS-3

See the table below for patents covering CATAPRES-TTS-3 around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	653933
Brazil	6463142
Switzerland	409980	Verfahren zur Herstellung von substituierten 2-Arylamino-1,3-diazacycloalkenen
Switzerland	437316	Verfahren zur Herstellung von substituierten Phenyl-amino-1,3-diazacyclopenten-(2)-Verbindungen
Switzerland	451169	Verfahren zur Herstellung neuer substituierter Phenylamino-1,3-diazacyclopentene-(2)
Switzerland	451172	Verfahren zur Herstellung neuer substituierter Phenylamino-1,3-diazacyclopentene-(2)
Cyprus	416	2-Aryl-amino-1,3-diazacyclopentenes

Last updated: June 1, 2026

CATAPRES-TTS-3 (clonidine transdermal system) market dynamics and financial trajectory

CATAPRES-TTS-3 (clonidine transdermal system, 3 mg delivered over 7 days) is a mature, off-patent antihypertensive launched in the branded late-life segment where generics dominate dispensing and pricing. Market trajectory is driven by (1) hypertension guideline adherence, (2) payer restrictions and prior authorization, (3) the continued substitution of brand with AB-rated generics of clonidine transdermal patches, and (4) sensitivity to wholesaler inventory cycles and seasonal prescribing. Financial performance tracks U.S. script volume and NRx-linked pharmacy reimbursement, with revenue upside limited by category maturity and the structural pricing disadvantage of branded products once generic coverage is broad.

Bottom line: CATAPRES-TTS-3 is an aging branded transdermal clonidine SKU with declining pricing power, stable use in patients preferring patches, and financial outcomes constrained by generic competition and formulary management.

---

How is CATAPRES-TTS-3 performing in the US prescription market?

CATAPRES-TTS-3 is marketed as a transdermal delivery form for clonidine, primarily used for hypertension and, in some practices, off-label indications such as neuropathic pain or withdrawal-related settings. The core market driver is long-term hypertension management rather than acute care, which tends to stabilize demand but does not protect pricing once generics are entrenched.

Key demand drivers

• Chronic use pattern: Hypertension treatment is long-duration, supporting baseline prescriptions even as overall penetration plateaus in a mature category.
• Patient preference for patch delivery: Transdermal clonidine can reduce dosing complexity relative to oral regimens, which can preserve a niche within patients who tolerate or prefer patches.
• Therapeutic substitution pressure: Generic clonidine patches typically carry lower net prices, increasing payer substitution and patient switching.

Category substitution dynamics

Transdermal clonidine competes with other antihypertensive classes on tolerability and outcomes. Within clonidine, AB substitution against authorized generics and multi-source product availability compresses brand pricing.

---

Why does generic competition dominate CATAPRES-TTS-3 market share?

The branded transdermal clonidine market is structurally exposed to generic entry because:

• clonidine is an established API with longstanding formulation and use coverage history,
• patch delivery products face lower barriers than complex biologics, and
• payer formularies reward lowest net cost for AB equivalents.

What changes in formularies typically do

• Step edits and prior authorization: can slow switching in the short term but often shift utilization once criteria are codified.
• Placement on preferred lists: accelerates substitution when generics are positioned as preferred.
• Copay assistance withdrawal: branded manufacturers often reduce affordability tools after generic saturation, increasing patient out-of-pocket pressure.

What happens to branded pricing

As generic shares rise, CATAPRES-TTS-3’s net realized price tends to decline faster than unit volume, dragging revenue even when scripts stabilize.

---

When do CATAPRES-TTS-3 revenues peak, and what drives the post-peak slide?

Branded products in mature antihypertensives typically peak on:

• early market adoption,
• limited generic coverage windows, and
• formulary inclusion before wide AB substitution.

For CATAPRES-TTS-3, the post-peak revenue trajectory is typically driven by:

1. Generic penetration and payer switching
2. Net price compression from rebates and contracting
3. Shrinking patient pool remaining on the brand due to pharmacy substitution

Inventory-cycle effects

Wholesaler de-stocking and restocking can produce short-term “lumpy” shipment patterns that overstate or understate underlying demand. Over a multi-quarter window, those effects usually fade while substitution continues.

---

What market dynamics affect clonidine transdermal patches versus oral clonidine?

Patch versus oral clonidine is often a distribution decision influenced by:

• patient adherence,
• side-effect profile (especially sedation and dry mouth),
• dosing frequency tolerance,
• insurance coverage differences by dosage form.

Where patches can hold up

• patients who cannot manage multiple daily doses,
• populations transitioning off oral regimens,
• payer plans with consistent coverage for specific transdermal NDCs.

Where oral can win

• lower total cost when oral generics are preferred,
• simplified formulary decisions if oral is placed as first-line within clonidine options.

---

What is the competitive landscape for CATAPRES-TTS-3 and clonidine transdermal patches?

The competitive set includes:

• generic clonidine transdermal systems (AB substitutes),
• therapeutic alternatives in hypertension (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, beta-blockers, and combination products),
• other clonidine delivery strategies in some markets (formulation-specific substitutes, not necessarily identical patch delivery).

Competitive implications

• In-class competition (clonidine patches): drives pricing and reduces branded share.
• Cross-class competition (other antihypertensives): affects total addressable demand when physicians switch class-level therapies.

---

What pricing and reimbursement pressures do branded CATAPRES-TTS-3 products face?

Branded patch products in late lifecycle usually experience:

• Net price decreases via payer contracting and performance-based rebates.
• Loss of channel support once generics are preferred and wholesaler demand shifts to multi-source SKUs.
• Reduced copay coverage which directly affects patient retention.

Expected financial effect

• unit volume stability without equivalent price stability results in flattening or declining revenue.
• revenue volatility can track contracting resets and channel inventory corrections.

---

What regulatory and FDA status factors influence CATAPRES-TTS-3 demand?

Demand for established clonidine products is largely insulated from major regulatory shocks, but can be affected by:

• label updates,
• safety communications,
• manufacturing quality actions that affect supply continuity.

Supply continuity as a revenue driver

If supply interruptions occur, pharmacies can switch to alternative strengths or AB equivalents. Persistent shortages often accelerate brand displacement. Once switching occurs, it can become stickier than short-term demand.

---

How does CATAPRES-TTS-3 compare financially with other transdermal antihypertensive brands?

Relative to other branded transdermal systems, branded clonidine patches tend to show:

• smaller revenue scale due to category maturity,
• greater exposure to AB substitution,
• less premium delivery advantage because oral generics are inexpensive.

Transdermal antihypertensives with stronger patent and exclusivity history typically retain pricing power longer. CATAPRES-TTS-3’s trajectory is therefore expected to look like a mature brand rather than a growing specialty patch.

---

What revenue exposure does CATAPRES-TTS-3 have from ongoing generics and payer actions?

The revenue exposure is dominated by:

• percentage of prescriptions captured by AB generics at pharmacy fill,
• plan-level contracting that sets CATAPRES-TTS-3 at a non-preferred tier,
• rebate economics that offset gross-to-net price but compress margins.

Typical scenarios

• Base case: stable but low single-digit unit share with declining net price.
• Downside: formulary downgrade and accelerated switching reduce both share and pricing, creating revenue decline faster than unit trends alone.
• Upside: temporary supply constraints for generics or limited coverage of specific patch strengths can lift branded fill rates briefly.

---

How strong is the patent estate for CATAPRES-TTS-3 and what does it mean for financial trajectory?

For CATAPRES-TTS-3, the financial trajectory is primarily a market structure outcome. Branded transdermal clonidine’s long-standing commercialization suggests that any remaining incremental protection, if present, would be narrow in scope and unlikely to counter broad AB competition at pharmacy level.

Practical financial impact

Even if some patents persist, pharmacy economics often favor generics unless the brand holds narrow exclusivity that materially limits therapeutic substitution.

---

Key Takeaways

• CATAPRES-TTS-3 is a mature branded clonidine transdermal product where generic substitution drives most market dynamics.
• The financial trajectory is constrained by net price compression and payer formulary management, not by underlying demand collapse.
• Revenue is most sensitive to fill share versus net price: stable scripts without price power tends to produce flat-to-declining revenue.
• Competitive pressure comes from both in-class generic clonidine patches and cross-class antihypertensive substitution.
• Supply continuity and contracting resets are key near-term levers for quarterly shipment and revenue volatility.

---

FAQs

1. What drives pharmacy-level switching from CATAPRES-TTS-3 to generic clonidine patches?
2. How do prior authorization and tier placement affect branded transdermal clonidine utilization?
3. Do clonidine transdermal patches maintain utilization when hypertension prescribing shifts toward combination therapies?
4. What supply constraints most often accelerate brand displacement for generic patch products?
5. How does net realized pricing typically evolve for branded dermatologic or transdermal antihypertensives after AB competition ramps?

---

References

[1] FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
[2] FDA Drug Label: CATAPRES-TTS-3 (clonidine transdermal system). U.S. Food and Drug Administration.
[3] FDA Prescription Drug Product with Active Ingredient Clonidine Transdermal System (Drug approvals and listings). U.S. Food and Drug Administration.